Identification, SAR Studies, and X-ray Co-crystallographic Analysis of a Novel Furanopyrimidine Aurora Kinase A Inhibitor

被引:28
作者
Coumar, Mohane Selvaraj [1 ]
Tsai, Ming-Tsung [1 ,2 ]
Chu, Chang-Ying [1 ]
Uang, Biing-Jiun [2 ]
Lin, Wen-Hsing [1 ]
Chang, Chun-Yu [1 ]
Chang, Teng-Yuan [1 ]
Leou, Jiun-Shyang [1 ]
Teng, Chi-Huang [1 ]
Wu, Jian-Sung [1 ]
Fang, Ming-Yu [1 ]
Chen, Chun-Hwa [1 ]
Hsu, John T-A [1 ,3 ]
Wu, Su-Ying [1 ]
Chao, Yu-Sheng [1 ]
Hsieh, Hsing-Pang [1 ]
机构
[1] Natl Hlth Res Inst, Div Biotechnol & Pharmaceut Res, Zhunan 350, Miaoli County, Taiwan
[2] Natl Tsing Hua Univ, Dept Chem, Hsinchu 300, Taiwan
[3] Natl Chiao Tung Univ, Dept Biol Sci & Technol, Hsinchu 300, Taiwan
关键词
aurora kinase inhibitors; hit identification; structural biology; structure-activity relationships; substructure searches; TARGETED LIBRARIES; ANTICANCER AGENTS; STRUCTURAL BASIS; PROTEIN-KINASES; DRUG TARGETS; POTENT; DESIGN; DISCOVERY; NITRILEN; INSIGHTS;
D O I
10.1002/cmdc.200900339
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Here in we reveal a simple method for the identification of novel Aurora kinase A inhibitors through substructure searching of an in-house compounds for testing. A hydrazone fragment conferring Aurora kinase activity and heterocyclic rings most frequently reported in kinase inhibitors were used as substructure queries to filter the in house compound library collection prior to testing. Five new series of Aurora kinase inhibitors were identified through this strategy with IC50 values ranging from similar to 300 nm to similar to 15 mu m, by testing only 133 compounds from a database of similar to 125 000 compounds. Structure activity relationship studies and X-ray co-crystallographic analysis of the most potent compound, a furanopyrimidine derivative with an IC50 value of 309 nm toward Aurora kinase A, were carried out. The knowledge gained through these studies could help in the future design of potent Aurora kinase inhibitors.
引用
收藏
页码:255 / 267
页数:13
相关论文
共 36 条
[1]   Kinase-targeted libraries: The design and synthesis of novel, potent, and selective kinase inhibitors [J].
Akritopoulou-Zanze, Irini ;
Hajduk, Philip J. .
DRUG DISCOVERY TODAY, 2009, 14 (5-6) :291-297
[2]  
ALI MM, 1995, INDIAN J HETEROCY CH, V4, P191
[3]   Kinase-likeness and kinase-privileged fragments: Toward virtual polypharmacology [J].
Aronov, Alex M. ;
McClain, Brian ;
Moody, Cameron Stuver ;
Murcko, Mark A. .
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (05) :1214-1222
[4]   Toward a pharmacophore for kinase frequent hitters [J].
Aronov, AM ;
Murcko, MA .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (23) :5616-5619
[5]   A minimalist approach to fragment-based ligand design using common rings and linkers: Application to kinase inhibitors [J].
Aronov, AM ;
Bemis, GW .
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2004, 57 (01) :36-50
[6]   Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug [J].
Capdeville, R ;
Buchdunger, E ;
Zimmermann, J ;
Matter, A .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) :493-502
[7]   A comprehensive update of the sequence and structure classification of kinases [J].
Cheek, S ;
Ginalski, K ;
Zhang, H ;
Grishin, NV .
BMC STRUCTURAL BIOLOGY, 2005, 5
[8]   Structural basis for potent inhibition of the Aurora kinases and a T3151 multi-drug resistant mutant form of Abl kinase by VX-680 [J].
Cheetham, G. M. T. ;
Charlton, P. A. ;
Golec, J. M. C. ;
Pollard, J. R. .
CANCER LETTERS, 2007, 251 (02) :323-329
[9]  
Cheung CHA, 2009, EXPERT OPIN INV DRUG, V18, P379, DOI [10.1517/13543780902806392 , 10.1517/13543780902806392]
[10]   Protein kinases - the major drug targets of the twenty-first century? [J].
Cohen, P .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) :309-315